Naloxegol (formerly NKTR-118; AZ-13337019; PEGylated naloxol; Movantik; Moventig) is a peripherally-active/selective μ-opioid antagonist approved in 2014 for the treatment of opioid-induced constipation. It was approved in 2014 by FDA to treat constipation caused by opiate pain medications in adults with chronic pain that is not caused by cancer. Structurally, naloxegol is a pegylated analog of α-naloxol.

纯度：≥98%

CAS：854601-70-0